Literature DB >> 22811776

Hats Off to HIT: A Case Report.

Akhwand Shakeel Ahmad, Dhia Jaber Al-Layla, Manjula Dhinakar.   

Abstract

Thrombocytopenia is a well- recognized complication of heparin therapy. The diagnosis is mostly clinical and the main value of laboratory testing is in excluding the diagnosis. We describe here a patient with stroke who had aspiration pneumonia leading to sepsis. She developed atrial fibrillation and received heparin which had to be stopped prematurely due to melena. Within 5 days of heparin, she had thrombocytopenia which was heparin-induced thrombocytopenia (HIT), but the diagnosis was missed initially as heparin was no longer on the drug chart.

Entities:  

Keywords:  Atrial fibrillation; Heparin-induced thrombocytopenia; Stroke

Year:  2012        PMID: 22811776      PMCID: PMC3394359          DOI: 10.5001/omj.2012.54

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  17 in total

Review 1.  How I treat heparin-induced thrombocytopenia and thrombosis.

Authors:  Barbara M Alving
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

2.  Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia.

Authors:  K Wanaka; T Matsuo; M Matsuo; C Kaneko; K Miyashita; R Asada; H Matsushima; Y Nakajima
Journal:  J Thromb Haemost       Date:  2009-12-24       Impact factor: 5.824

3.  Delayed-onset heparin-induced thrombocytopenia.

Authors:  Lawrence Rice; Walid K Attisha; Alane Drexler; John L Francis
Journal:  Ann Intern Med       Date:  2002-02-05       Impact factor: 25.391

Review 4.  Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis.

Authors:  A Greinacher
Journal:  Semin Thromb Hemost       Date:  1995       Impact factor: 4.180

5.  Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.

Authors:  P M Newman; B H Chong
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

6.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.

Authors:  Nadine Martel; James Lee; Philip S Wells
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

7.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Theodore E Warkentin; Andreas Greinacher; Andreas Koster; A Michael Lincoff
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 8.  Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.

Authors:  Allison Beck Blackmer; Maryann D Oertel; John M Valgus
Journal:  Ann Pharmacother       Date:  2009-09-08       Impact factor: 3.154

9.  Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia.

Authors:  Abhay F Srinivasan; Lawrence Rice; John R Bartholomew; Chandhiran Rangaswamy; Lucy La Perna; James E Thompson; Scott Murphy; Kelty R Baker
Journal:  Arch Intern Med       Date:  2004-01-12

10.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

View more
  1 in total

1.  Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock.

Authors:  Pravin Patel; Noor F Shaik; Yuhang Zhou; Kalyan Golla; Steven E McKenzie; Ulhas P Naik
Journal:  J Thromb Haemost       Date:  2020-09-09       Impact factor: 5.824

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.